title: Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients.
abstract: OBJECTIVE
  To evaluate the efficacy and tolerance of amantadine in combination with interferon in the treatment of chronic hepatitis C.
  
  
  METHODS
  Multi-centre trial including 180 chronic hepatitis C patients without cirrhosis, randomly enrolled to receive interferon 6 MU every other day for 6 months followed by 3 MU for further 6 months (group A, 90 patients), or the same schedule plus amantadine 200 mg/day (group B, 90 patients). Primary end-point was a sustained virological and biochemical response, secondary end-points were on-treatment (third month) and end-of-treatment response rates.
  
  
  RESULTS
  The two groups had similar demographic, biochemical and virological characteristics. A sustained response after 6 months follow-up was observed in 17% of group A and 24% of group B patients (P not significant), an end-of-treatment response was observed in 37% in group A and 47% in group B (P not significant), an on-treatment response was observed in 46% in group A and 61% in group B patients (P < 0.05). No major side effects due to amantadine administration were observed.
  
  
  CONCLUSIONS
  Adding amantadine to interferon did not improve the sustained treatment efficacy. However, the rate of early response at the third month of therapy was significantly higher in the combination therapy group.
authors.affiliation: Internal Medicine IV, Molinette Hospital, Turin, Italy. gastroentero@mauriziano.it
authors.forename: M
authors.initials: M
authors.lastname: Tabone
authors.forename: C
authors.initials: C
authors.lastname: Laudi
authors.forename: B
authors.initials: B
authors.lastname: Delmastro
authors.forename: A
authors.initials: A
authors.lastname: Biglino
authors.forename: M
authors.initials: M
authors.lastname: Andreoni
authors.forename: F
authors.initials: F
authors.lastname: Chieppa
authors.forename: R
authors.initials: R
authors.lastname: Bonardi
authors.forename: G
authors.initials: G
authors.lastname: Cariti
authors.forename: S
authors.initials: S
authors.lastname: Cusumano
authors.forename: F
authors.initials: F
authors.lastname: Brunello
authors.forename: G
authors.initials: G
authors.lastname: Calleri
authors.forename: A
authors.initials: A
authors.lastname: Manca
authors.forename: P
authors.initials: P
authors.lastname: Della Monica
authors.forename: L
authors.initials: L
authors.lastname: Sidoli
authors.forename: M
authors.initials: M
authors.lastname: Rizzetto
authors.forename: A
authors.initials: A
authors.lastname: Pera
mesh_terms: D000328:Adult; D000547:Amantadine / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007372:Interferons; D000547:Amantadine